Medizinportal Arztsuche Apothekensuche KliniksucheHealth Provider Directory - Health in Germany - english-language-version
Home DocSearch ClinicSearch HealthSites

News

2009-07-14:
Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point - of - Care Bacteria Test
Lake Zurich, Illinois ( PRN/ots ) - Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today it has signed a five - year exclusive worldwide agreement with Verax Biomedical Incorporated to market, sell and distribute Verax's unique (...)
2006-10-03:
Isotechnika Receives European Patent for Lead Immunosuppressive Drug, ISA247
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that the Company has been issued European Patent No. EP0991660 for its lead immunosuppressive drug, ISA247. The patent entitled "DEUTERATED AND UNDEUTERATED CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS" is the ninth patent to be (...)
2006-09-05:
RIVIERA Registry Identifies Modifiable Predictors of Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention
Barcelona, Spain ( PRN/ots ) - Results of the multinational, prospective, observational RIVIERA registry ( Registry on IntraVenous anticoagulation In the Elective and primary Real world of Angioplasty ) announced today at the World Congress of Cardiology 2006 - joint meeting of the European Society of Cardiology & World Heart (...)
2010-05-26:
Your Story, Your Voice, Your Achievements, Your Ideas (...) This Is About Life, Real Life, Real MS
Geneva, May 26, 2010 ( PRN/ots ) - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced the launch of Real MS today on World MS Day 2010. Real MS, a global multiple sclerosis ( MS ) awareness campaign, aims to unite the voice of those (...)
2007-09-18:
Groupe Novasep to Acquire PharmaChem Technologies ( Grand Bahama ) Ltd
Pompey, France ( PRN/ots ) - - Combined Company Will Become one of the Leading Suppliers for the Life Science Industries Groupe Novasep announced today that the company is finalizing discussions to acquire Bahamas - based PharmaChem Technologies ( Grand Bahama ) Ltd for an undisclosed amount. The (...)
2007-06-18:
More Than Half of Hypertensive Patients Remain Uncontrolled and at Higher Risk of Heart Attack and Stroke - Telmisartan May Decrease This Risk
Milan, Italy ( PRN/ots ) - - For non - US Healthcare Media - Results From Two Large, Multinational, Practice - Based Observational Studies in Blood Pressure New data announced today at the Annual European Society of Hypertension ( ESH ) show that measuring blood pressure in a doctor's office (...)
2007-09-13:
Roche Launches Another Large Study With PEGASYS Plus COPEGUS
Basel, Switzerland ( PRN/ots ) - - PROPHESYS Will Identify Factors That Influence Early Response to Treatment Roche announces the start of a large multinational observational study, called PROPHESYS, in patients with hepatitis C ( HCV ). This international cohort study will evaluate the important factors that give (...)
2007-03-16:
Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment
Carlsbad, California ( PRN/ots ) - - Start of Phase 1 Clinical Trial Planned for the Second Half of This Year Micromet, Inc. ( Nasdaq: MITI ), a biopharmaceutical company focused on the development of novel and proprietary antibody - based products for cancer, inflammatory and autoimmune diseases, (...)
2011-03-01:
BARACLUDE( R ) ( entecavir ) Approved by the European Commission for the Treatment of Chronic Hepatitis B in Adult Patients With Evidence of Decompensated Liver Disease
Paris ( PRN/ots ) - Bristol - Myers Squibb announced today that BARACLUDE( R ) ( entecavir ) has been approved by the European Commission on February 28th 2011 to treat chronic hepatitis B ( CHB ) in adult patients with evidence of decompensated liver disease. BARACLUDE( r ) was already approved in Europe (...)
2008-09-01:
SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
Washington ( PRN/ots ) - - One - Year Data Find Angioplasty and Stenting Safe and Effective in Patients for Whom Standard Therapy Has Been Open - Heart Surgery Data announced today from the landmark SYNTAX trial indicate that patients with very complex coronary artery disease (...)
2009-03-11:
European Commission Approves ReFacto AF( TM ) as a Variation to the Refacto( R ) Marketing Authorisation
Maidenhead, England ( PRN/ots ) - - Improvements in Purification Process Represent Important Advance in the Treatment of Haemophilia A Wyeth announced today it has received a positive decision from the European Commission for a variation of the marketing authorisation for ReFacto moroctocog alfa ( Recombinant (...)
2006-10-17:
Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent
New York ( PRN/ots ) - Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy. Ranbaxy can appeal (...)
2004-10-07:
Adis International Recognized for its Strong Dedication to Employee Development
Chester, England ( PRN/ots ) - - Accepts Prestigious 2004 'Investors in People' Award Wolters Kluwer Health, Pharma Solutions business unit today announced that Adis International was named a 2004 "Investor in People" by the Investors in People UK Recognition Panel. The London - based organization (...)
2004-09-03:
New European Study Examines the Role of Insulin Resistance in Predicting Cardiovascular Disease
London and Brussels ( PRN/ots ) - - RISC Study, Largest of its Kind, Reaches Recruitment Milestone The European Group for the study of Insulin Resistance ( EGIR ) announced today that the clinical trial recruitment milestone of 1,200 subjects has been reached in the Relationship (...)
2008-07-21:
Update on the SEAS Study
London ( PRN/ots ) - Professor Terje Pedersen ( Ullevål University Hospital, Oslo, Norway ), lead investigator for the Simvastatin and Ezetimibe in Aortic Stenosis ( SEAS ) Study, will provide an update on the study on Monday the 21st July. Also present in London will be Sir Richard (...)
2005-05-09:
Reservations for Goodie Bags American Pavilion 2005 Cannes Film Festival
New York ( PRN/ots ) - The VIP goodie bag company, Madison & Mulholland ( M|M ) created a limited edition of 50 goodie bags for the American Pavilion 2005 Cannes Film Festival. As word got out about this hot US$4000 goodie bag, phones have started (...)
2006-07-27:
PharmaMar Submits Marketing Authorization Application in Europe for Yondelis( R ) In Soft Tissue Sarcoma
Madrid ( PRN/ots ) - PharmaMar today announces the submission of a Marketing Authorization Application to the European Medicines Agency ( EMEA ) for Yondelis( R ) ( trabectedin ) as a treatment for soft tissue sarcomas ( STS ). The application is based on the results of a randomised, Phase II pivotal study (...)
2007-08-29:
AstraZeneca's Once - Daily SEROQUEL XR( TM ) Extended - Release Tablets Approved in Netherlands for the Acute and Long Term Treatment of Schizophrenia
London ( PRN/ots ) - - For International Medical Journalists Only AstraZeneca today announced the Netherlands regulatory authority MEB ( Medicines Evaluation Board ) has approved SEROQUEL XR( TM ) ( quetiapine fumarate ) Extended - Release Tablets, a once - daily medicine for the treatment of schizophrenia in adult patients. With SEROQUEL XR( TM ) (...)
2006-11-17:
Women With Early Breast Cancer are More Likely to Remain Cancer Free by Changing Treatment From Tamoxifen to Arimidex( TM ) ( Anastrozole )
Macclesfield, England, November 17 ( PRN/ots ) - FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA - Data Published in the Lancet Oncology Report That Patients are More Likely to Live Cancer Free for Longer if Tamoxifen is Replaced With ARIMIDEXT( TM ) According to data published (...)
2008-10-02:
Driving Change in Mental Health Through Science and Community
Beerse, Belgium ( PRN/ots ) - Today, Janssen - Cilag are celebrating their 50 year commitment to researching and developing innovative medicines to help improve the lives of people with mental health problems. Back in 1958, the late Dr. Paul Janssen developed one of the first anti - (...)
2006-09-26:
Sanofi pasteur Cell Culture - Based Seasonal Influenza Vaccine Enters First Clinical Trial
SWIFTWATER, Pennsylvania & LYON, France, September 26 ( PRN/ots ) - - Flu Vaccine Based on New Technology Within U.S. Government Preparedness Program Sanofi pasteur, the vaccines business of the sanofi - aventis Group ( NYSE: SNY ), initiated its first clinical study today with a new generation of (...)
2007-06-15:
Inovelon( R ) A New Treatment for Lennox - Gastaut Syndrome Launched in Europe
London ( PRN/ots ) - - First Treatment Licensed Specifically for LGS Offers New Hope for Patients With Epilepsy Eisai Europe Limited, ( Headquarters: London, President Yutaka Tsuchiya ) today announced the launch in Germany and Scandinavia of its new anti - epileptic agent Inovelon ( rufinamide ) indicated for adjunctive (...)
2009-09-30:
Superior Efficacy - dose Ratio for Lantus( R ) Over detemir
Paris ( PRN/ots ) - - 76 Prozent Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus( R ) Sanofi - aventis ( EURONEXT: SAN and NYSE: SNY ) announced today results of a head - to - head study providing further evidence on the efficacy of (...)
2010-06-28:
New High - Resolution Computer Tomography Data Demonstrates EVISTA( R )'s Effect on Bone Quality in Osteoporotic Patients
Munich, June 28, 2010 ( PRN/ots ) - Interim data from a prospective Investigator Initiated Trial ( IIT ) presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA( R ) ( raloxifene 60mg; once - daily, distributed in 34 countries by DAIICHI SANKYO ), indicated (...)
2009-11-16:
Flibanserin Demonstrates Efficacy and Tolerability in Pivotal Phase III Trials in Pre - Menopausal Women With Hypoactive Sexual Desire Disorder ( HSDD )
Ingelheim, Germany, November 16 ( PRN/ots ) - - Results Support Flibanserin as a Potential Treatment for HSDD, an Under - Recognised Women's Sexual Health Condition - For Medical Media, Outside the US Only Data from pooled, pivotal Phase III clinical trials demonstrate that flibanserin 100mg (...)
2004-12-06:
LAB International to Initiate Phase II Trial for GHRH
Laval, Canada ( PRN/ots ) - - Malnutrition in Patients With Late Pre - end - stage Chronic Renal Failure Selected as Clinical Indication for Trial LAB International Inc. ( TSX: LAB ), an integrated drug development company focused on the inhalation market, today announced that, after completion of (...)
2007-03-12:
Isotechnika Receives USAN Approval for Generic Name for Lead Immunosuppressive Drug
Edmonton, Canada ( PRN/ots ) - Isotechnika Inc. announced today that the Company has received approval from United States Adopted Name ( USAN ) for naming of its lead immunosuppressive drug, ISA247. The name, voclosporin, is now being reviewed by the International Nonproprietary Name ( INN ) expert committee. The (...)
2007-02-26:
U.S. Regulators Approve Cymbalta( R ) for Treatment of Generalised Anxiety Disorder
Indianapolis ( PRN/ots ) - The U.S. Food and Drug Administration ( FDA ) has approved the antidepressant Cymbalta( R ) ( duloxetine HCl ) for the treatment of generalised anxiety disorder ( GAD ), Eli Lilly and Company ( NYSE: LLY ) and Boehringer Ingelheim announced today. The approval is based on the (...)
2005-09-26:
FDA Accepts for Filing a License Application for New Pediatric Combination Vaccine, PENTACEL( TM )
Lyon, France et Swiftwater, Pennsylvanie ( PRN/ots ) - - First Combination Vaccine Candidate in the U.S. Designed to Protect Infants and Young Children against Diphtheria, Tetanus, Pertussis, Polio, and Hib Sanofi pasteur, the vaccines business of the sanofi - aventis Group ( EURONEXT: SAN ), ( NYSE: SNY ), (...)
2004-12-17:
Abbott Announces European and U.S. Regulatory Submissions for Humira( R ) as Treatment for Psoriatic Arthritis
Abbott Park, Illinois ( PRN/ots ) - - First expansion into new disease for rheumatoid arthritis drug HUMIRA Abbott ( NYSE: ABT ) announced it has simultaneously submitted a Marketing Authorization Application ( MAA ) to the European Medicines Agency ( EMEA ) and a supplemental Biologics License Application ( sBLA ) with the (...)
2009-04-17:
New Partnerships Added to World Federation of Hemophilia Twinning Program
Collegeville, Pennsylvania ( PRN/ots ) - - Wyeth and Advocacy Community Mark Continued Commitment to Patient Care on World Hemophilia Day In honor of the twentieth Anniversary of World Hemophilia Day, Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), together with the World Federation of (...)
2009-06-08:
Final Call for Entries to the 'Excellence in Epilepsy' Journalism Award
Brussels ( PRN/ots ) - The 'Excellence in Epilepsy' Journalism Award - an initiative of the International Bureau for Epilepsy ( IBE ) and UCB - invites journalists from around the world to submit stimulating, informed and compelling news and feature stories on epilepsy. The award seeks to increase awareness (...)
2005-10-21:
BOLDER II Study Confirms Therapeutic Potential of SEROQUEL in Bipolar Depression
Alderley Park, England ( PRN/ots ) - - For Health Professional Press and Non - UK Journalists Only Newly released top - line results from the BOLDER II ( BipOLar DEpRession ) study have underlined the potential for SEROQUEL ( quetiapine fumarate ) in the treatment of patients with major depressive (...)
2005-05-24:
BioWa and Medarex Announce Expansion of Licensing Agreement for BioWa's Potelligent( TM ) Technology
Princeton, New Jersey ( PRN/ots ) - - BioWa Grants the Second Potelligent( TM ) Antibody Technology License to Medarex BioWa, Inc. and Medarex, Inc. ( Nasdaq: MEDX ) today announced that BioWa has granted a second license to Medarex to use BioWa's Potelligent( TM ) Technology for the enhancement of (...)
2006-02-24:
Boehringer Ingelheim Receives Recommendation From EU Scientific Committee for Sifrol( R )/ Mirapexin( R ) ( Pramipexole ) for the Treatment of Restless Legs Syndrome ( RLS )
Ingelheim, Germany ( PRN/ots ) - - For Non - US Healthcare Professional Media Boehringer Ingelheim announced today that that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMEA ) has issued a positive opinion recommending approval of Sifrol( R ) / Mirapexin( R ) ( pramipexole ) (...)
2007-06-02:
Study Supports Activity of GEMZAR( R ) ( Gemcitabine HC1 for Injection ) in the Treatment of Early - Stage Breast Cancer
Chicago ( PRN/ots ) - - Five Phase III Early - Stage Breast Cancer Studies Underway With GEMZAR GEMZAR( R ) ( gemcitabine HC1 for injection ), approved in combination with paclitaxel ( Taxol( R ) ) in the first - line, post - surgical treatment of metastatic breast cancer, was the subject of a study (...)
2008-05-29:
New Published Data Support Safety and Efficacy of RESOLOR( R ) for Treatment of Chronic Constipation
Turnhout, Belgium ( PRN/ots ) - - New Generation Compound Provides Significant Benefit in Patients who do not Adequately Respond to Laxatives New phase III data for RESOLOR( R ) ( prucalopride ) published today in The New England Journal of Medicine ( NEJM ) shows statistically and clinically significant improvement (...)
2008-02-22:
Astellas Receives Positive Opinion From CHMP for Mycamine( R ) for the Treatment of Serious Fungal Infections
Staines, England ( PRN/ots ) - - New Treatment Option Contributes to Fight Against Healthcare Associated Infections Astellas Pharma Europe Ltd( i ) announced today that the Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMEA ) issued a positive opinion by consensus, (...)
2007-10-15:
Valdoxan( R ), the First Melatonergic Antidepressant, Confirms its Efficacy in Preventing Relapse Whatever the Severity of the Depression
Vienna, Austria ( PRN/ots ) - Valdoxan( R ) ( agomelatine ), the first melatonergic antidepressant, is an effective, long - term treatment for Major Depressive Disorder ( MDD ) according to new data presented today at the European College of Neurospsychopharmacology ( ECNP ) annual congress. The new international study showed Valdoxan's efficacy in preventing (...)
2009-11-17:
FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
Lake Zurich, Illinois, November 17 ( PRN/ots ) - - Experts to Re - examine Guidance for Platelet Testing Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has cleared (...)
2007-09-25:
New Data Shows Bowel Cancer Patients Live Longer on Xeloda
Barcelona, Spain ( PRN/ots ) - Abstract no: 1LB, being presented at ECCO "Gastrointestinal malignancies - colorectal cancer 1" session in room 110, starting at 09.00 on Tuesday 25 September 2007 BARCELONA, Spain, September 25 /PRNewswire/ - - - 5 Year Data Confirm Superiority of Xeloda Over (...)
2008-11-11:
DAIICHI SANKYO and Arqule enter Into Strategic R&D Partnership to Progress Novel Compounds to Target Cancer
Munich ( na Originaltextservice ) - Product development agreement focused on ARQ 197, c - Met inhibitor, with discovery collaboration directed toward novel kinase inhibitors ArQule, Inc. ( NASDAQ: ARQL ) and DAIICHI SANKYO Co., Ltd. ( TSE: 4568 ) today announced that they have entered into (...)
2009-03-23:
With New National Immunisation Programme in Saudi Arabia, Thirty - Five Countries Now Offer Routine Immunisation Against Pneumococcal Disease With Prevenar
Maidenhead, England ( PRN/ots ) - - Prevenar Helps Protect Children Against the Leading Vaccine - Preventable Cause of Death in Children Younger than Five Years of Age Worldwide Wyeth today announced that Prevenar( TM ) ( Pneumococcal saccharide conjugated vaccine, Adsorbed ) has been added to Saudi Arabia's national childhood (...)
2007-06-02:
Avastin( R ) Significantly Prolongs Progression Free Survival in Advanced Kidney Cancer
Chicago ( PRN/ots ) - - Patients Have a Chance to Live Almost Twice as Long Without Their Disease Returning Adding Avastin ( bevacizumab ) to interferon offers patients with advanced renal cell cancer the chance to live twice as long without their disease advancing ( "progression free (...)
2007-06-02:
New Data Show Bondronat( R ) Prevents Bone Loss Caused by anastrozole in Women With Surgically Treated Breast Cancer
Chicago, Illinois ( PRN/ots ) - - One Year Results From the ARIBON Study Presented at ASCO 2007 Bondronat( R ) ( ibandronic acid ) has been shown to prevent bone loss caused by anastrozole in post - menopausal women given adjuvant therapy for early breast cancer according to (...)
2010-07-22:
Kowa Announces Successful EU Regulatory Application for Pitavastatin
Wokingham, England, July 22, 2010 ( PRN/ots ) - Kowa are delighted to announce that following the completion of the decentralized regulatory procedure, that their statin, pitavastatin has achieved a positive outcome from the UK Regulatory Authority ( MHRA ) acting as the Reference Member State for 16 (...)
2011-03-08:
ProFibrix Initiates Phase II With Lead Hemostasis Product Fibrocaps( TM ) in US and Europe
Leiden, The Netherlands and Seattle ( PRN/ots ) - ProFibrix B.V., a leader in the development of innovative products for hemostasis, today announced that it has initiated a prospective, multi - center Phase II study with its lead product Fibrocaps at up to 20 sites, including (...)
2008-05-07:
Astellas' Mycamine( R ) ( micafungin ) Licensed for Use in Europe to Treat Serious Fungal Infections
Staines, England ( PRN/ots ) - The European Medicines Agency ( EMEA ) has announced the marketing authorisation of Mycamine( R ), Astellas Pharma Europe's treatment for invasive candidiasis, oesophageal candidiasis and prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem cell transplantation. Mycamine( R ) will initially be available in the (...)
2006-05-22:
New Evidence Validates Global Prevalence and Severity of Abdominal Cramping and Pain
Ingelheim, Germany ( PRN/ots ) - - For Healthcare Professional and Consumer Journalists - Not for Distribution to USA Media - Survey Shows 25 Prozent of World's Population Suffer From Common and Distressing Ailment That can be Effectively Treated New data presented at the premier international (...)

back... 1 2 3 4 5 6 7 8 9 10 11 more...



» German Health-Sites

Medical and health related Websites from Germany

Alternative Medicine
Beauty and Wellness
Manufacturers of Medical Equipment
Biotechnology
International
Databases
German Doctors Worldwide
German Medicine and Patient Transfer
Special Diagnoses
Acne
Cancer
Diabetes
Nutrition and Diet
Family
Fitness and Sports
Forums
Womens Health
Genetics
Health-Marketing
Dating
Health Insurance
Other Insurances
Literature and Publishers
Newspaper / Magazines
Organizations
Care
Portals and Directories
Pharmacies
Portals and Directories Dental Medicine
Search
Psyche
Public Health
Governmental Links
Guides
Regional
Baden-Wuerttemberg
Bavaria
Berlin
North Rhine-Westphalia
Travel Medicine
Self-Help
AIDS
Alcoholism
Alzheimer
Medical malpractice
Visually Impaired
Seminar
Seniors / 50+
Seniors / Living
Shopping
Medical Technology
Children-, Youth- and Social Work
Scholastics
Accommodation
Organization
Mixed


© 2003-2008 med-kolleg.de Health Provider Directory
Clinics and Physicians
Berlin, Germany Montag, 17.6.2019.
Sitemap (Sitemap German) Imprint Press (German)
Ärzteverzeichnis Klinikverzeichnis Apothekenverzeichnis Ärztesuche
 Sun, 16 Jun 2019 12:17:23 GMT
Werben im Gesundheitssektor / Medizin

Health Provider Directory

Medizin und Gesundheit - Arztsuche Kliniksuche Apothekensuche
Gesundheitsportal